Recent Advances in Melanoma

Grace Cherry, RN, ​MSN, NP, Melanoma Program, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses ​recent advances in melanoma. 

Significant progress ​has been made in the treatment landscape of melanoma, says Cherry. Moreover, ongoing research suggests that certain combination therapies can re-induce an immune response in patients who progress on PD-1 inhibitors. 

 Moreover, on July 30, 2020, the FDA approved atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) for patients with BRAF V600​–mutation positive advanced melanoma based on findings from the ​phase 3 IMspire150 trial.

This is a valuable addition to the armamentarium, Cherry concludes.